JAK1/2 inhibition promotes aggressive cutaneous carcinogenesis through COT kinase–mediated alternative MAPK pathway activation
Journal of Clinical Investigation · 02.11.2026 · 136 (21)
DOI: 10.1172/jci199141 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 02.11.2026. Verfasst von Hélène Pasquer und 27 weiteren Autor:innen. Beteiligte Einrichtung: INSERM UMR 1342, Institut de Recherche Saint-Louis, Paris, France. Hauptthemen laut MEDLINE: Pyrazoles, Skin Neoplasms, Janus Kinase 2, MAP Kinase Signaling System. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Secondary malignancies are the most feared adverse effects of cancer therapies. In this study, we explored the cutaneous oncogenic effects of the JAK inhibitor ruxolitinib. First, we demonstrated an epidemiological association between ruxolitinib exposure and development of aggressive cutaneous squamous cell carcinoma (cSCC) by analyzing international pharmacovigilance data and conducting a large cohort study. We next demonstrated the causal link between ruxolitinib treatment and cSCC development using in vitro and in vivo models. Mechanistically, we revealed that ruxolitinib induces transformation of premalignant keratinocytes by activating the MAPK pathway. This effect is mostly driven by JAK2 inhibition, suggesting a pharmacological class effect. To unravel the mechanistic underpinnings of ruxolitinib-induced MAPK activation, we then applied a phosphoproteomic approach. Alternative MAPK signaling downstream of the kinase COT was pinpointed as the main activator of the pathway in this context. The central role of COT was functionally validated using chemical inhibition, genetic impairment, and inactivated COT mutant expression. Indeed, impairment of COT rescued the pro-oncogenic effect of ruxolitinib. Finally, we determined using a combination of epidemiological, in vitro, and in vivo studies that ruxolitinib-mediated oncogenic effects also result in an increased risk of melanoma, suggesting that the uncovered cellular signaling mechanism might be extrapolated to other cancers with a high dependency on the MAPK pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- INSERM UMR 1342, Institut de Recherche Saint-Louis, Paris, France.
- Université Paris Cité, INSERM Clinical Investigation Center (CIC) 1427, AP-HP, Hôpital Saint-Louis, Paris, France.
- Quantitative Biosciences Institute and.
- Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, California, USA.
- Service de Pathologie, INSERM U976, Institut de Recherche Saint-Louis, and.
- Dermato-oncology Unit and CIC, Cancer Institute AP-HP.Nord Paris Cité, INSERM U976, Université Paris Cité, AP-HP, Hôpital Saint-Louis, Paris, France.
Zitieren
APA
Pasquer, H., Forget, A., Battistella, M., Marie, R., Provent, L., Baroudjian, B., Latour, E., Culeux, C., Roux, B., Saadallah, K., Gouverneur, A., Demourgues, M., Jouenne, F., Lambert, J., Lombard, B., Loew, D., Tartare-Deckert, S., Adès, L., Raffoux, E., …, & Benajiba, L. (2026). JAK1/2 inhibition promotes aggressive cutaneous carcinogenesis through COT kinase–mediated alternative MAPK pathway activation. Journal of Clinical Investigation, 136(21). https://doi.org/10.1172/jci199141
Vancouver
Pasquer H, Forget A, Battistella M, Marie R, Provent L, Baroudjian B, et al. JAK1/2 inhibition promotes aggressive cutaneous carcinogenesis through COT kinase–mediated alternative MAPK pathway activation. Journal of Clinical Investigation. 2026;136(21). doi:10.1172/jci199141
BibTeX
@article{Pasquer2026,
author = {Pasquer, Hélène and Forget, Antoine and Battistella, Maxime and Marie, Raphael and Provent, Léa and Baroudjian, Barouyr and Latour, Emmanuelle and Culeux, Cécile and Roux, Blandine and Saadallah, Khansa and Gouverneur, Amandine and Demourgues, Maxime and Jouenne, Fanélie and Lambert, Jérôme and Lombard, Bérangère and Loew, Damarys and Tartare-Deckert, Sophie and Adès, Lionel and Raffoux, Emmanuel and Cassinat, Bruno and Soret-Dulphy, Juliette and Noize, Pernelle and Mourah, Samia and Lobry, Camille and Kiladjian, Jean-Jacques and Puissant, Alexandre and Lebbé, Céleste and Benajiba, Lina},
title = {JAK1/2 inhibition promotes aggressive cutaneous carcinogenesis through COT kinase–mediated alternative MAPK pathway activation},
journal = {Journal of Clinical Investigation},
year = {2026},
volume = {136},
number = {21},
doi = {10.1172/jci199141}
}
EUVIMED